Form 4: Nurix Therapeutics Executive Christine Ring Reports Stock Transactions
SEC Form 4 Filing
Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.
Summary
- On June 5, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, exercised stock options to acquire 400 shares of common stock at a price of $1.86 per share.
- Simultaneously, Ms. Ring sold 400 shares of common stock at a weighted average price of $17.0025 per share.
- These transactions were executed under a pre-existing Rule 10b5-1 trading plan.
- Following these transactions, Ms. Ring beneficially owns 19,838 shares of Nurix Therapeutics common stock and holds options for 98,070 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 09/09/2020 | Option vested as to 1/4 of the total shares |
| 08/09/2023 | Option fully vested |
| 06/05/2024 | Date of transaction: Exercise of stock options and sale of shares |
| 09/30/2029 | Expiration date of employee stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.